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Abstract 
Background: It is not clear how severe metabolic syndrome (MS) affects the development of coronary 
atherosclerosis.
Methods: This was an observational, retrospective cohort study with Koreans who received health check‑ups volun‑
tarily. A total of 2426 subjects had baseline and follow‑up coronary artery calcium score (CACS) data. Among them, 
1079 had coronary computed tomography angiography (CCTA) data. We compared baseline CACS and any progres‑
sion in subjects with and without MS. A more detailed analysis was conducted for coronary artery disease (CAD), 
which was defined by coronary artery stenosis (≥50 %), multivessel involvement, and coronary plaques in those 
patients with CCTA data.
Results: At baseline, subjects with MS (34.0 %, n = 825) had higher CACS and more significant coronary artery 
stenosis, multivessel involvement, and atheromatous plaques than those without MS (P < 0.05 for all). In the follow‑up 
(median 1197 days), subjects with MS showed significant increases in CACS and progression of CAD compared with 
counterparts without MS, in parallel with the numbers of MS components. Finally, MS was a significant predictor for 
the progression of CACS (hazard ratio 1.32; 95 % confidence interval 1.06–1.64) and progression of coronary artery 
stenosis and/or development of vulnerable plaque (hazard ratio 1.47, 95 % confidence interval 1.01–2.15) after adjust‑
ing for other cardiovascular risk factors.
Conclusions: Subjects with MS showed progression of CAD as assessed by CACS and CCTA over ~3 years. Therefore, 
more vigilant screening for coronary vascular health is needed among those with MS.
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Background
Cardiovascular disease is the leading cause of deaths 
worldwide [1]. According to a report of the World Health 
Organization in 2009, 30  % of all global deaths were 
attributed to cardiovascular diseases in 2008. It is also 
estimated that by 2030, over 23 million people will die 
from cardiovascular diseases each year [2, 3]. Thus, there 
is a major social cost in the management of cardiovascu-
lar disease.
Under these circumstances, it is worthwhile to pre-
screen subjects for subclinical coronary atherosclerosis 
and manage risk factors to prevent its development and 
progression. There are several methods of screening for 
cardiovascular disease, such as electrocardiograms, the 
ankle-to-brachial blood pressure index, pulse wave veloc-
ity, carotid intima-media thickness, N-terminal pro-brain 
natriuretic peptide, the presence of carotid plaques, coro-
nary artery calcium score (CACS), and coronary artery 
stenosis [4–8].
Among these, CACS is used widely as a screening 
method [9]. CACS reflects the presence and the extent of 
coronary atherosclerosis and has an independent associa-
tion with cardiovascular events [10]. It has been used for 
individualized risk stratification and for predicting out-
comes [11, 12]. The American Heart Association has sug-
gested that CACS is a reasonable tool to assess the risk 
of cardiovascular disease [13]. Moreover, repeated CACS 
measures were found to be useful in predicting cardio-
vascular outcomes and in assessing the effectiveness of 
treatments [14–16].
In the recent decade, there has been much progress in 
technologies in coronary computed tomography angi-
ography (CCTA). This is able to provide more detailed 
information than CACS, including the degree of steno-
sis in individual coronary arteries, plaque characteris-
tics, and the extent of any vascular remodeling [17–19]. 
We have reported that the evaluation of possible coro-
nary artery disease (CAD) with multidetector CCTA is 
of importance in the early diagnosis of atherosclerosis in 
asymptomatic patients, particularly for assessing plaque 
characteristics [20].
Metabolic syndrome (MS) is a disorder, characterized 
by clusters of cardiovascular risk factors such as visceral 
obesity, high blood pressure, dyslipidemia, and impaired 
glucose tolerance [21]. Studies have confirmed that peo-
ple with MS have an increased risk of cardiovascular 
morbidity and mortality [22].
There have been several studies supporting the rela-
tionship between MS and high burden of CACS [23, 
24]. We have reported the association between MS and 
cardiovascular disease using multidetector CCTA [20]. 
However, longitudinal follow-up studies investigating the 
impact of MS on coronary vascular health using CACS or 
multidetector CCTA are limited [25]. Therefore, the aim 
of this study was to investigate the association of any pro-
gression of CACS and CAD with the severity of MS in a 
large Korean population, using CACS and CCTA.
Methods
Study population
This study was an observational, retrospective cohort 
study. Among people (n > 10,000 per year) who partici-
pated in a routine health check-up at Seoul National Uni-
versity Hospital Healthcare System Gangnam Center, a 
total of 17,390 subjects who had at least one or more car-
diovascular risk factors, or who had atypical chest pain, 
underwent a CCTA from October 1, 2003 to Decem-
ber 31, 2012. Among them, 14,765 subjects who did not 
have follow-up CCTA scans until December 2013 were 
excluded. Next, 18 subjects who had medical histories of 
coronary revascularization at baseline were excluded. We 
also excluded those subjects whose CACS or coronary 
vascular health were not adequately evaluated (n = 97) or 
who had missing data for defining MS (n = 98).
Finally, a total of 2426 subjects who had a baseline and 
a follow-up CACS at least 1 year apart were included in 
the analysis. The median follow-up period was 1197 days 
(interquartile range 766.0‒1687.5). Among these sub-
jects, 1079 underwent CCTA tests at baseline and a 
follow-up CCTA test at least 1  year later. In this sub-
group, we evaluated the progression of CAD by assess-
ing the degree of coronary artery stenosis and presence 
of plaques and its characteristics. Selection of the study 
participants is outlined in Fig. 1.
The study protocol conformed to the ethical guidelines 
of the Declaration of Helsinki (2013). It was approved 
by the institutional review board of Seoul National Uni-
versity Hospital (IRB No. H-1501-003-635). All patients 
underwent multidetector CT after they had agreed to 
participate in the study and had provided informed con-
sent after being informed of the possible risks of CT 
scanning.
Anthropometric measurement and laboratory evaluations
On the day of the CT scan, anthropometric parameters 
such as height, body weight, waist circumference, and 
systolic and diastolic blood pressures were measured by 
trained nurses. Body mass index (BMI) was calculated as 
weight divided by height in kg/m2. Waist circumference 
was measured at the midpoint between the lower costal 
margin and the iliac crest.
Each subject completed a self-administered question-
naire, which included questions on demographic factors; 
a medical history covering diabetes mellitus (DM), dys-
lipidemia, hypertension, coronary revascularization, and 
drug use; family history of cardiovascular disease; and a 
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social history including smoking habit, alcohol consump-
tion, and levels of physical activity.
Smoking status was defined as follows: Patients were 
classified as current smokers if they currently smoked 
for at least 1 year. Patients were classified as nonsmokers 
if they had never smoked. Patients were classified as ex-
smokers if they had smoked but quit. Patients were clas-
sified as nondrinkers or current drinkers by determining 
their average daily alcohol consumption. Nondrinkers 
were those who had not consumed alcohol within the 
past 30 days. Physical activity was classified into two cat-
egories: none or regular exercise. Regular exercise was 
defined as exercising more than three times a week (each 
session should be at least 30 min).
For biochemical tests, fasting plasma concentrations 
of glucose, total cholesterol, triglycerides, high-density 
lipoprotein (HDL)-cholesterol, and serum high-sensitiv-
ity C-reactive protein (hsCRP) were measured using an 
Architect Ci8200 analyzer (Abbott Laboratories, Abbott 
Park, IL, USA). Glycated hemoglobin (HbA1c) levels 
were measured using a COBAS INTEGRA 400 instru-
ment (Roche Diagnostics GmbH, Mannheim, Germany). 
Plasma insulin concentrations were measured by radioim-
munoassay (Linco, St. Louis, MO, USA). Aspartate/alanine 
aminotransferase (AST/ALT), gamma-glutamyl trans-
peptidase (γGT), and creatinine were measured using an 
Architect Ci8200 analyzer (Abbott Laboratories, Abbott 
Park, IL, USA). Low-density lipoprotein (LDL)-cholesterol 
concentration was calculated using the Friedewald equa-
tion [26]. In subjects with a triglyceride level ≥400 mg/dL, 
the measured LDL-cholesterol was used for analysis.
The homeostasis model assessment of insulin resistance 
(HOMA-IR) and pancreatic β-cell function (HOMA-β) 
were calculated as described by Matthews et  al. [27]. 
HOMA-IR =  fasting insulin (µIU/mL) ×  fasting plasma 
glucose (mg/dL)/405; HOMA-β  =  360×  fasting insulin 
(µIU/mL)/[fasting plasma glucose (mg/dL) − 63].
Diabetes mellitus was defined as a fasting plasma glucose 
level of 126 mg/dL (7 mmol/L) or higher or current antidia-
betic treatment. Hypertension was defined as systolic/dias-
tolic blood pressure measures greater than 140/90 mmHg or 
current treatment with antihypertensive medication. Dyslip-
idemia was defined as an LDL-cholesterol level of 160 mg/dL 
or higher or current use of a lipid-lowering agent.
Fig. 1 Selection of study participants
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Evaluation of initial coronary CT angiography
In all subjects, coronary CT was performed either with a 
16-slice scanner (Somatom Sensation 16; Siemens Medi-
cal Solutions, Forchheim, Germany) or with a 256-slice 
multidetector CT scanner (Brilliance iCT 256; Philips 
Medical Systems, Cleveland, OH, USA). A standard scan-
ning protocol was applied, with 128 × 0.625 mm section 
collimation, 0.27 ms rotation time, 120 kV tube voltage, 
and 800 mA tube current. All scans were performed with 
electrocardiogram-gated dose modulation. Two expe-
rienced radiologists—blinded to all clinical informa-
tion and patient demographics—analyzed all CT scans. 
The CACS was calculated quantitatively as described by 
Agatston et al. [28] using dedicated software (Rapidia 2.8; 
INFINITT, Seoul, South Korea).
Coronary artery stenosis and plaque characteristics 
were evaluated in the subjects who underwent multi-
detector CCTA. The coronary lumen cross-sectional 
diameter was traced at the maximal stenotic site and 
compared with the mean value for the proximal and dis-
tal reference sites. Coronary artery stenosis was evalu-
ated according to five categories as follows: (1) normal 
or minimal (absence of plaque and no stenosis to plaque 
with  <25  % stenosis); (2) mild (25–49  % stenosis); (3) 
moderate (50–69  % stenosis); (4) severe stenosis (70–
99 % stenosis); and (5) occluded (100 % stenosis) [29, 30]. 
We recorded the degree of stenosis in each segment for 
one vessel and finally defined the maximal stenosis as 
being the grade of stenosis used in analysis for that vessel. 
Significant stenosis was defined as the presence of at least 
moderate stenosis. We also defined multivessel involve-
ment when there was the presence of ≥50 % stenosis in at 
least two vessels.
Plaque characteristics were evaluated by arterial seg-
ment: left main artery; proximal, middle, and distal 
segment of left anterior descending artery; left circum-
ferential artery; and right coronary artery. Each plaque 
was classified as calcified, mixed, or noncalcified type: 
(1) plaques that contained calcified tissue comprising 
≥50 % of the plaque area were classified as calcified; (2) 
plaques with <50 % calcium in the plaque area were clas-
sified as mixed; and (3) plaques without any calcium were 
classified as noncalcified lesions [31]. If there was any 
plaque on a segment, we counted it as an atherosclerotic 
coronary segment. If there was a mixed or a noncalci-
fied plaque, it was defined as a vulnerable atheromatous 
plaque [32, 33] (Additional file 1: Figure S1). Definition of 
metabolic syndrome
In accordance with modified National Cholesterol Edu-
cation Program–Adult Treatment Panel III criteria [34, 
35], an individual was classified as having MS if he or she 
had three or more of the flowing five criteria: (1) waist 
circumference ≥90  cm in men and ≥80  cm in women, 
using the International Obesity Task Force criteria for 
the Asian–Pacific population to determine waist cir-
cumference criteria [36]; (2) triglyceride levels ≥150 mg/
dL (1.7  mmol/L); (3) HDL-cholesterol level  <40  mg/dL 
(1.0  mmol/L) in men and  <50  mg/dL (1.3  mmol/L) in 
women; (4) blood pressure ≥130/85  mmHg or the use 
of antihypertensive medication; and (5) fasting glucose 
level ≥100 mg/dL (6.1 mmol/L) or the self-reported use 
of antidiabetic medication (insulin or oral agents).
Assessment of progression of coronary artery disease 
on cardiac CT
CACS progression was the main outcome measure of 
this study, which was assessed according to Berry et  al. 
[37]. In patients with absence of any calcification at base-
line (CACS = 0), progression was defined as CACS > 0 
at follow-up. In subjects with a CACS  >  0 and  <100, 
progression was defined as an annualized increase of at 
least 10 Agatston units at follow-up, and for those with 
a CACS  ≥  100, an annualized percentage increase of 
≥10 % at the follow-up was defined as progression.
For secondary outcome 1, progression of coronary 
artery stenosis was defined by the following conditions: 
(1) progression in the grade of stenosis at the vessel where 
the original stenosis was identified; and (2) generation of 
new stenosis at other segments. For secondary outcome 
2, the development of new vulnerable plaque was defined 
as when any mixed or noncalcified plaque had developed 
in one or more segments.
Statistical analysis
We compared data using Student’s t tests for continuous 
variables and χ2 tests for categorical variables. All data 
are expressed as the mean  ±  standard deviation (SD), 
median (interquartile range), or number (frequency). 
Log transformation was used for the statistical analysis of 
CACS, HOMA-IR, and hsCRP. χ2 tests with linear-by-lin-
ear associations were applied to examine the significance 
of any linear trend of CAD progression according to the 
number of MS components. A Cox proportional hazard 
model was used to investigate any independent effect of 
MS on the progression of CAD. The analyses were per-
formed using IBM SPSS Statistics for Windows (version 




Baseline characteristics and biochemical parameters were 
compared according to the presence or absence of MS 
(Table 1). Baseline characteristics according to the gender 
were presented in the Additional file 1: Table S1. At base-
line, 825 subjects had MS (34.0  % of total population). 
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Their mean age was about 56 years and similar between 
the MS group and those without MS. The subjects with 
MS had higher BMI, larger waist circumference, and 
higher blood pressure, as expected with the definition of 
MS.
The MS group had a significantly greater impairment 
in glucose tolerance and higher insulin resistance than 
did the group without MS (P  <  0.05). The HOMA-β 
results were not different between the two groups. Liver 
enzyme activities such as the levels of AST, ALT, and 
γGT were significantly higher in the MS group than in 
the group without it (P  <  0.05). Serum triglyceride lev-
els were higher and HDL-cholesterol levels were signifi-
cantly lower in the MS group than in the groups without 
MS (both P  <  0.05). Serum LDL-cholesterol levels were 
significantly higher in the group without MS, but there 
lower LDL-cholesterol level in the MS group could 
be attributed to their used of medication. The rates of 
hypertension, DM, and dyslipidemia were significantly 
higher in the MS group than in the group without MS. 
The proportions of subjects who were taking medications 
for hypertension, DM, and dyslipidemia were also signifi-
cantly greater in the MS group than in the group without 
MS. Smoking status, alcohol consumption, and exercise 
habits did not differ between the two groups.
Cardiac CT findings according to the presence of metabolic 
syndrome
At baseline, the mean ±  SD of CACS in the MS group 
was significantly greater than that in the group without 
MS (103.7 ± 270.9 vs. 71.3 ± 225.1, P < 0.01). The pro-
portion of subjects with coronary calcium (CACS  >  0) 
was also higher in the MS group than in the group with-
out MS (54.4 vs. 45.8 %; P < 0.001).
In the MS group, 52.6 % of subjects showed CACS pro-
gression, while in the group without MS, 40.4 % of sub-
jects had progressed (P < 0.001). In the subgroup of 1079 
subjects with data concerning the degree of coronary 
artery stenosis and coronary plaque using CCTA at base-
line, significantly more subjects with MS had significant 
stenosis (13.6 vs. 8.9 %; P = 0.017), multivessel involve-
ment (4.2 vs. 1.7  %; P  =  0.015), and coronary plaques 
(55.1  vs.  43.3  %; P  <  0.001) than did those without MS. 
In the follow-up, the subjects with MS showed a trend of 
progression of stenosis than did the group without MS 
(28.6  vs.  23.4  %; P =  0.067). Furthermore, the develop-
ment of vulnerable plaque (mixed or noncalcified types) 
was larger in the MS group than group without MS with 
borderline significance (Table 2).
Next, we evaluated any association between the num-
ber of MS components and progression of CAD. As the 
number of MS components increased, so did the pro-
gression of CACS. The proportion of subjects with CACS 
progression increased gradually from 30.9 % in subjects 
without any MS component to 66.0  % in those with all 
five components (P for trend  <0.001; Fig.  2a). A similar 
Table 1 Baseline clinical and  biochemical characteristics 
in subjects with and without metabolic syndrome (MS)
Data are shown as the mean and (SD) or percentages
MS metabolic syndrome, SBP systolic blood pressure, DBP diastolic blood 
pressure, HbA1c glycated hemoglobin, HOMA-IR homeostasis model assessment 
of insulin resistance, HOMA-β homeostasis model assessment of pancreatic 
β-cell function, γGT γ-glutamyl transpeptidase, HDL high-density lipoprotein, 
LDL low-density lipoprotein, hsCRP high sensitivity C-reactive protein
a Log-transformed values were used for analysis
MS (n = 825) Non-MS (n = 1601) P
Clinical and anthropometric parameters
 Age, years 56.6 (7.5) 56.2 ± 7.2 0.180
 No. (%) of male 661 (80.0) 1278 (79.8) 0.873
 Height, cm 167.5 (7.6) 166.7 (7.4) 0.010
 Weight, kg 73.8 (10.3) 66.5 (9.1) <0.001
 BMI, kg/m2 26.2 (2.6) 23.9 (2.3) <0.001
 Waist circumference, cm 92.7 (6.6) 85.9 (6.4) <0.001
 SBP, mmHg 127.5 (13.8) 118.5 (14.3) <0.001
 DBP, mmHg 83.8 (10.5) 77.8 (10.5) <0.001
Biochemical parameters
 Fasting glucose, mmol/L 6.37 (1.30) 5.49 (0.93) <0.001
 HbA1c,  % 6.1 (0.8) 5.8 (0.6) <0.001
 Insulin, μU/mL 12.3 (5.6) 8.5 (4.1) <0.001
 HOMA‑IRa 3.48 (1.74) 2.12 (1.10) <0.001
 HOMA‑βa 97.6 (57.8) 95.0 (54.2) 0.434
 AST, IU/L 28.9 (14.0) 24.8 (9.3) <0.001
 ALT, IU/L 34.3 (21.5) 26.2 (14.7) <0.001
 γGT, IU/L 55.6 (59.5) 35.7 (30.8) <0.001
 Creatinine, µmol/L 93.70 (17.68) 93.70 (15.03) 0.884
 Total cholesterol, mmol/L 5.13 (0.93) 5.18 (0.88) 0.147
 Triglyceride, mmol/L 2.04 (104.1) 1.18 (0.58) <0.001
 HDL‑cholesterol, mmol/L 1.21 (0.29) 1.42 (0.32) <0.001
 LDL‑cholesterol, mmol/L 3.02 (0.87) 3.23 (0.81) <0.001
 hsCRPa, mg/dL 0.17 (0.42) 0.14 (0.44) 0.118
Comorbidity and lifestyles
 Hypertension (%) 70.9 32.8 <0.001
 Diabetes mellitus (%) 32.3 12.7 <0.001
 Dyslipidemia (%) 37.5 27.6 <0.001
Medication
 Hypertension (%) 58.0 23.5 <0.001
 Diabetes mellitus (%) 18.9 7.5 <0.001
 Dyslipidemia (%) 36.0 22.8 <0.001
Smoking status 0.119
 Current smoker (%) 12.7 11.6
 Ex‑smoker (%) 43.2 39.9
 Never smoker (%) 44.1 48.5
 Current drinker (%) 74.3 73.0 0.673
 Regular exercise (%) 34.5 35.5 0.654
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trend was observed when the progression was evalu-
ated using the degree of coronary artery stenosis (P for 
trend = 0.001; Fig. 2b) or the development of vulnerable 
plaque (P for trend = 0.005; Fig. 2c).
Multivariable analysis of primary and secondary outcomes
We performed multivariable analyses with Cox propor-
tional hazard models to investigate any independent 
effect of MS on the progression of CAD (Table 3). First, 
the presence of MS was significantly associated with 
the progression of CACS after adjusting for age and sex 
(hazard ratio [HR], 1.68, 95  % confidence interval [CI], 
1.39–2.03, P < 0.001) (Model A) and additional adjusting 
for smoking habit and family history of CAD (HR 1.67; 
95 % CI, 1.38–2.20: P < 0.001) (Model B). After further 
adjusting for BMI, and the levels of LDL-cholesterol and 
HbA1c, the presence of MS was significantly linked with 
the progression of CACS with slight attenuation (HR 
1.32; 95 % CI 1.06–1.64; P = 0.012) (Model C).
Next, we performed the same analysis using CCTA 
data. The presence of MS was significantly associated 
with the progression of coronary artery stenosis or the 
development of vulnerable plaque after adjusting for 
age and sex (HR 1.45; 95  % CI 1.06–1.99; P  =  0.021) 
(Model A) and additional adjusting for smoking habit 
and a family history of CAD (HR 1.44; 95  % CI 1.05–
1.99; P =  0.025) (Model B). After further adjusting for 
BMI, and the levels of LDL-cholesterol and HbA1c, a 
significant association of the presence of MS with the 
progression of coronary artery stenosis or development 
of vulnerable plaque was maintained (HR 1.47; 95 % CI 
1.13–2.15; P = 0.045) (Model C).
Discussion
In this large retrospective longitudinal study, the sub-
jects with MS had more CAD than those without MS at 
baseline. More importantly, those with MS showed rapid 
development or progression of CACS, coronary artery 
stenosis, and vulnerable plaque in the longitudinal fol-
low-up, with a positive association with the number of 
MS components. MS was found to be an independent 
predictor for CAD progression even after adjusting for 
multiple relevant risk factors.
The CACS, one of the indicators of subclinical CAD, 
is correlated strongly with the extent of atherosclero-
sis [9]. According to the Jackson Heart Study, the pres-
ence of a high CACS was directly associated with the 
incidence of cardiovascular disease [38]. High CACS 
Table 2 Comparison of cardiac computed tomography findings between subjects with and without metabolic syndrome 
(MS)
CCTA coronary computed tomography angiography, CACS coronary artery calcium score, FU follow-up, IQR interquartile range
a Log-transformed values were used for analysis
MS Non-MS P
Baseline data
 CACS n = 825 n = 1601
  Initial CACS, median (IQR) 11.1 (0‒98.5) 0.0 (0‒43.0) <0.001a
  Prevalence of coronary calcification, n (%) 449 (54.4) 734 (45.8) <0.001
 CCTA n = 381 n = 698
  Significant stenosis, n (%) 52 (13.6) 62 (8.9) 0.017
  Multivessel disease, n (%) 16 (4.2) 12 (1.7) 0.025
  Any plaque, n (%) 210 (55.1) 302 (43.3) <0.001
Plaque type
 Calcified, n (%) 156 (40.9) 233 (33.4) 0.463
 Mixed, n (%) 60 (15.7) 82 (11.7) 0.764
 Non‑calcified, n (%) 41 (10.8) 63 (9.0) 0.739
Follow up data
 CACS n = 825 n = 1601
  FU interval, median (IQR), days 1285 (763.3‒1640.3) 1292 (763.5‒1703.0) 0.808
  Follow‑up CACS, median (IQR) 45.3 (0‒225.3) 10.4 (0‒115.4) <0.001a
  Progression of CACS, n (%) 434 (52.6) 647 (40.4) <0.001
 CCTA n = 381 n = 698
  FU interval, median (IQR), days 1106 (735.0‒1484.6) 1102 (741.8‒1465.3) 0.948
  Progression of stenosis, n (%) 109 (28.6) 163 (23.4) 0.067
  Development of vulnerable plaque, n (%) 95 (24.9) 138 (19.8) 0.053
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was associated with arterial stiffness measured by aor-
tic pulse wave velocity, which is another potential pre-
dictor of cardiovascular events [39]. There have been 
many cross-sectional studies investigating the associa-
tion between MS and the high burden of coronary artery 
calcium [40–44]. Wong et  al. [45] showed that indi-
viduals with MS had a greater degree of progression of 
CACS compared with those without MS. Moreover, it 
was reported that nonalcoholic fatty liver disease, which 
is now recognized as the hepatic manifestation of MS 
and insulin resistance, has a significant association with 
CACS [46, 47]. These studies suggest that CACS is an 
effective marker for evaluating CAD and further forms of 
CVD, as mentioned above.
However, measurement of calcium deposition only in 
coronary arteries seems not sufficient to evaluate CAD 
precisely. Even though CACS is an established surrogate 
marker for coronary atherosclerosis [13], it cannot pro-
vide detailed information on CAD such as the degree 
of coronary artery stenosis or plaque characteristics. 
Direct assessment of individual coronary vessels seems 
to be more helpful for assessing coronary vascular 
health than simple calcium deposition. Detailed evalu-
ation of plaque characteristics is also of importance 
in this context. In fact, mixed or noncalcified plaques 
occur more frequently in patients with an acute coro-
nary syndrome than in those with stable angina [48], 
and are known to be associated with a higher all-cause 
mortality outcome than calcified plaques [49]. These 
findings suggest that vulnerable plaques might trigger 
plaque rupture and are more associated with poor car-
diovascular outcome [32].
So far, only a few studies have shown an association 
between MS and the degree of stenosis/plaque charac-
teristics assessed by CCTA [20, 50]. We have reported 
previously that MS was significantly associated with non-
calcified/mixed plaques in a large number of study par-
ticipants, suggesting that CCTA is a useful tool in the 
detailed evaluation of subclinical coronary atheroscle-
rosis for individuals at high risk [20]. Furthermore, few 
studies have evaluated the influence of MS on the devel-
opment or progression of CAD using CCTA in longitudi-
nal studies [25]. To the best of our knowledge, our study 
is the largest that has investigated the influence of MS 
on development and/or progression of CAD as assessed 
comprehensively by CCTA in a longitudinal setting.
Here, we confirmed previous reports by demonstrating 
that people with MS had a greater extent of coronary cal-
cification and a higher prevalence of significant coronary 
stenosis, multivessel involvement, and coronary plaques 
than those without MS [40–43]. Furthermore, we found 
a significant rate of progression of CACS in the follow-
up. Significantly more progression of coronary artery 
stenosis or greater development of vulnerable plaque was 
also found in the subjects with MS than those without 
MS in the follow-up with CCTA. Among all the subjects 
Fig. 2 Proportions of CAD progression according to the number of 
the metabolic syndrome (MS) components present. a Proportion 
of patients with CACS progression. b Proportions of progression 
evaluated by the degree of coronary stenosis. c Proportions of the 
development of vulnerable plaque, according to the numbers of 
components of MS
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(n = 2426) enrolled in this study, 1079 underwent CCTA 
tests both at baseline and at least 1  year later. Of these 
subjects, 155 (14.4 %) had significant progression of cor-
onary artery stenosis and/or development of vulnerable 
plaques without CACS progression. This finding sup-
ports our conclusion that CCTA is able to provide more 
sensitive information about CAD progression than sim-
ple CACS.
This study had several strengths. First, comprehensive 
evaluations including medical history, anthropometric 
measurements, and biochemical parameters were pos-
sible because data were collected through the general 
health check-up. Second, we analyzed long-term follow-
up data, so that we could determine any independent 
association of MS with the progression of CAD. Third, 
we analyzed detailed information about the degree of 
coronary stenosis and plaque characteristics using CCTA 
with advanced technology.
Our study also had several limitations. First, it was a 
retrospective, longitudinal study so there might have 
been confounders that were not corrected sufficiently. 
Second, the study participants, who voluntarily under-
went a health check-up, might not have been repre-
sentative of the general Korean population. Also, their 
health-seeking behavior and the interventions possibly 
taken after the baseline evaluation might have changed 
their cardiovascular risk profiles during the study period 
and could attenuate the relationship between MS and the 
progression of CAD. Third, a comprehensive evaluation 
of CAD using CCTA was available in only 44.5 % of the 
study participants.
Conclusions
We confirmed that MS is associated with coronary ath-
erosclerosis as evidenced by significant coronary artery 
stenosis, multivessel involvement, and/or high plaque 
burden as well as high CACS. Subjects with MS showed 
greater progression not only in the CACS, but also in the 
degree of coronary stenosis and vulnerable plaque forma-
tion. Thus, our study has confirmed that MS is an inde-
pendent risk factor for the progression of CAD even after 
adjusting for known cardiovascular risk factors. These 
findings suggest that more vigilant screening for sub-
clinical CAD is helpful in individual with MS and more 
aggressive management for cardiovascular risk factors 
is required to prevent any progression of CAD in these 
subjects.
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